Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer

Inclusion Criteria: * diagnosis of ovarian cancer * age \>18 yrs, * ECOG performance status 0-3, * expected life expectancy \>6 months, * 1-5 synchronous lesions * any site of disease, * compulsory assessment of mutational status of BRCA1/2 genes (either germline or somatic), * salvage surgery or other local therapies not feasible, * relative contraindication to further systemic therapy because of serious comorbidities, * previous severe systemic therapy toxicity * unavailability of potentially active systemic therapy, * patient refusal of systemic therapy, * Re-treatment of lesions already treated with conventional external beam radiotherapy is allowed\* Exclusion Criteria: * mucinous OC, * borderline ovarian tumors, * non-epithelial OC, * previous radiotherapy severe toxicity * co-morbidities and functional impairment considered clinically precluding the safe use of SBRT, * pregnancy * any psychological, sociological, or geographical issue potentially hampering compliance with the study, * lesion diameter larger than 5 centimeters